指南与共识

ESMO关于日常实践与临床研究中检测NTRK融合标准方法的推荐

ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research.
指南 / 共识 · Ann Oncol · 2019-01-01

ESMO转化研究与精准医学工作组组织专家综述NTRK1/2/3融合检测方法并形成共识。可用的技术包括免疫组化、FISH、RT-PCR及基于RNA或DNA的新一代测序,各有优劣。在NTRK融合高发肿瘤中可用FISH、RT-PCR或RNA测序面板确认,在低发人群中建议一线测序(优先RNA测序)或免疫组化筛查后对阳性病例测序。

要点

  • NTRK1/2/3融合是TRK小分子抑制剂使用的生物标志物。
  • 检测技术包括免疫组化、FISH、RT-PCR及RNA/DNA-based NGS。
  • 高发肿瘤用FISH、RT-PCR或RNA测序面板确认;低发人群一线RNA测序或免疫组化筛查后测序。

核心结论

  • 在NTRK融合高发肿瘤中,FISH、RT-PCR或RNA-based测序面板可作为确认技术。
  • 在NTRK1/2/3融合不常见的未选择人群中,应进行一线测序(优先RNA测序)或免疫组化筛查后对阳性病例测序。

研究设计与样本

  • ESMO转化研究与精准医学工作组(TR and PM WG)招募多个机构专家,综述NTRK基因融合检测的可用方法、潜在应用及合理实施策略,形成共识并经ESMO TR and PM WG和ESMO领导层审核批准。

主要发现

  • NTRK1、NTRK2和NTRK3融合存在于多种组织学类型的恶性肿瘤中,是这些受体酪氨酸激酶最常见的致癌激活机制及TRK小分子抑制剂使用的生物标志物。
  • NTRK融合基因检测的主要技术包括免疫组化、荧光原位杂交(FISH)、RT-PCR以及基于RNA和基于DNA的新一代测序(NGS)。
  • 每种技术均有优势和局限性,筛查和最终诊断的检测方法选择还应考虑资源和临床背景。

关键数值与推荐

  • 在NTRK融合高发肿瘤中,FISH、RT-PCR或RNA-based测序面板可用作确认技术。
  • 在NTRK1/2/3融合不常见的未选择人群中,应采用一线测序(优先RNA测序)或免疫组化筛查后对阳性病例进行测序。

临床怎么用

  • 根据肿瘤类型中NTRK融合的频率选择检测策略:高发肿瘤可直接用FISH、RT-PCR或RNA测序面板确认;低发人群优先一线RNA测序或免疫组化筛查后测序。
  • 检测方法的选择需结合当地资源与临床背景。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: NTRK1, NTRK2 and NTRK3 fusions are present in a plethora of malignancies across different histologies. These fusions represent the most frequent mechanism of oncogenic activation of these receptor tyrosine kinases, and biomarkers for the use of TRK small molecule inhibitors. Given the varying frequency of NTRK1/2/3 fusions, crucial to the administration of NTRK inhibitors is the development of optimal approaches for the detection of human cancers harbouring activating NTRK1/2/3 fusion genes. MATERIALS AND METHODS: Experts from several Institutions were recruited by the European Society for Medical Oncology (ESMO) Translational Research and Precision Medicine Working Group (TR and PM WG) to review the available methods for the detection of NTRK gene fusions, their potential applications, and strategies for the implementation of a rational approach for the detection of NTRK1/2/3 fusion genes in human malignancies. A consensus on the most reasonable strategy to adopt when screening for NTRK fusions in oncologic patients was sought, and further reviewed and approved by the ESMO TR and PM WG and the ESMO leadership. RESULTS: The main techniques employed for NTRK fusion gene detection include immunohistochemistry, fluorescence in situ hybridization (FISH), RT-PCR, and both RNA-based and DNA-based next generation sequencing (NGS). Each technique has advantages and limitations, and the choice of assays for screening and final diagnosis should also take into account the resources and clinical context. CONCLUSION: In tumours where NTRK fusions are highly recurrent, FISH, RT-PCR or RNA-based sequencing panels can be used as confirmatory techniques, whereas in the scenario of testing an unselected population where NTRK1/2/3 fusions are uncommon, either front-line sequencing (preferentially RNA-sequencing) or screening by immunohistochemistry followed by sequencing of positive cases should be pursued.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Marchiò C, Scaltriti M, Ladanyi M, et al. ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research. Ann Oncol. 2019. PMID: 31268127. doi:10.1093/annonc/mdz204

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。